DXCM earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 29.76. Updated 2026-07-23.
DexCom (DXCM) Research Hub
DexCom (DXCM) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 83.03 USD (-1.01%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 29.76, market cap 27.85B. This hub links to the full technical, earnings and options research available for DXCM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 83.03 USD (-1.01%) |
| 52-week range | 67.3 USD – 92.56 USD |
| Trend regime | Range |
| 14-day RSI | 46.7 (Neutral) |
| Trailing P/E | 29.76 |
| Market cap | 27.85B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for DXCM
Covered Call on DXCM: how it works, illustrative setup around the real 83.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DXCM: how it works, illustrative setup around the real 83.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DXCM: how it works, illustrative setup around the real 83.03 USD price, max profit/loss, breakeven and when to use it. Educational.
DXCM technical analysis: range, last 83.03 USD, RSI 46.7, 52w range 67.3 USD–92.56 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DXCM in?
DexCom (DXCM) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is DXCM in an uptrend or downtrend?
As of 2026-09-11, DXCM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DXCM's trailing P/E ratio?
DXCM's trailing P/E is 29.76, with a market cap of 27.85B. See the earnings research page for full valuation detail.
When does DXCM next report earnings?
DXCM is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 0.61 USD.